PTC Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . PTC Therapeutics
PTCT Stock  USD 43.88  1.23  2.73%   
PTC Therapeutics financial statements provide useful quarterly and yearly information to potential PTC Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on PTC Therapeutics financial statements helps investors assess PTC Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting PTC Therapeutics' valuation are summarized below:
Gross Profit
2.6 M
Profit Margin
(0.50)
Market Capitalization
3.5 B
Enterprise Value Revenue
3.0767
Revenue
900.7 M
There are currently one hundred twenty fundamental measures for PTC Therapeutics that can be evaluated and compared over time across peers in the sector. All traders should check out PTC Therapeutics' latest fundamentals against the performance from 2010 to 2024 and make sure the trends continue to evolve in the right direction. Enterprise Value is likely to gain to about 3.9 B in 2024, whereas Market Cap is likely to drop slightly above 1.3 B in 2024.

PTC Therapeutics Total Revenue

984.71 Million

Check PTC Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among PTC Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 135.6 M, Total Revenue of 984.7 M or Research Development of 699.9 M, as well as many indicators such as Price To Sales Ratio of 2.09, Dividend Yield of 0.0 or Days Sales Outstanding of 51.74. PTC financial statements analysis is a perfect complement when working with PTC Therapeutics Valuation or Volatility modules.
  
Check out the analysis of PTC Therapeutics Correlation against competitors.
For more information on how to buy PTC Stock please use our How to Invest in PTC Therapeutics guide.

PTC Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets2 B1.9 B939.4 M
Slightly volatile
Other Current Liabilities405.2 M385.9 M124.4 M
Slightly volatile
Total Current Liabilities633.3 M603.1 M208.7 M
Slightly volatile
Other Liabilities263.2 M309.9 M261.6 M
Slightly volatile
Accounts Payable9.9 M6 M9.6 M
Slightly volatile
Cash623.7 M594 M310.3 M
Slightly volatile
Other Assets40.3 M38.4 M16.1 M
Slightly volatile
Short Term Investments281.6 M282.7 M255.8 M
Slightly volatile
Total Liabilities2.8 B2.7 B926.8 M
Slightly volatile
Property Plant Equipment87.7 M83.5 M33.8 M
Slightly volatile
Short and Long Term Debt Total2.3 B2.2 B489.9 M
Slightly volatile
Property Plant And Equipment Net187.9 M179 M59.7 M
Slightly volatile
Current Deferred Revenue761 K801 K23.8 M
Pretty Stable
Non Current Assets Total479.9 M677.1 M410.9 M
Slightly volatile
Non Currrent Assets Other34.8 M36.2 M29.8 M
Slightly volatile
Cash And Short Term Investments450.9 M876.7 M387.2 M
Slightly volatile
Net Receivables169.1 M161 M58.3 M
Slightly volatile
Common Stock Total Equity45.3 K82.8 K41.5 K
Slightly volatile
Common Stock Shares Outstanding49.7 M74.8 M44 M
Slightly volatile
Liabilities And Stockholders Equity1 B1.9 B875.1 M
Slightly volatile
Non Current Liabilities Total2.2 B2.1 B721.5 M
Slightly volatile
Property Plant And Equipment Gross241.8 M230.3 M71 M
Slightly volatile
Total Current Assets1.3 B1.2 B513.5 M
Slightly volatile
Short Term Debt220.8 M210.3 M64.6 M
Slightly volatile
Common Stock48.1 K75 K41.2 K
Slightly volatile
Capital Surpluse1.6 B2.7 B1.3 B
Slightly volatile
Non Current Liabilities Other133.9 K141 K247 M
Slightly volatile
Long Term Debt Total690.4 M657.5 M250.4 M
Slightly volatile
Short and Long Term Debt107.6 M194.3 M99.9 M
Pretty Stable
Net Invested Capital698 M1.3 B483.3 M
Slightly volatile
Net Working Capital497.7 M615.5 M322.3 M
Slightly volatile
Capital Stock73.5 K75 K58.8 K
Slightly volatile
Capital Lease Obligations131.4 M130.8 M114.8 M
Slightly volatile

PTC Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Revenue984.7 M937.8 M307.3 M
Slightly volatile
Research Development699.9 M666.6 M272.1 M
Slightly volatile
Depreciation And Amortization248.4 M236.6 M57.9 M
Slightly volatile
Selling General Administrative366.4 M349 M154.6 M
Slightly volatile
Other Operating Expenses1.4 B1.3 B493.3 M
Slightly volatile
Total Operating Expenses1.4 B1.3 B488.3 M
Slightly volatile
Interest Income10.5 M14.4 M8.1 M
Slightly volatile
Reconciled Depreciation204.5 M194.8 M55.7 M
Slightly volatile
Non Recurring26.7 M30 M32.7 M
Slightly volatile

PTC Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Capital Expenditures126.6 M120.6 M41.1 M
Slightly volatile
End Period Cash Flow640.8 M610.3 M185.2 M
Slightly volatile
Stock Based Compensation137.8 M131.2 M50.9 M
Slightly volatile
Begin Period Cash Flow310.7 M295.9 M124.5 M
Slightly volatile
Depreciation248.4 M236.6 M57.2 M
Slightly volatile
Other Non Cash Items158.9 M151.3 M46.1 M
Slightly volatile
Sale Purchase Of Stock89.2 M64 M123 M
Slightly volatile
Change To Netincome79 M130.8 M64.8 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio2.092.199311.1795
Pretty Stable
Days Sales Outstanding51.7462.669759.8062
Slightly volatile
Average Payables2.1 M2.4 M2.6 M
Slightly volatile
Stock Based Compensation To Revenue0.130.13990.2546
Pretty Stable
Capex To Depreciation0.610.50980.7057
Slightly volatile
EV To Sales3.753.94289.7974
Pretty Stable
Inventory Turnover2.252.14170.9542
Slightly volatile
Days Of Inventory On Hand162170597
Slightly volatile
Sales General And Administrative To Revenue0.80.520.7895
Very volatile
Research And Ddevelopement To Revenue0.680.71081.2951
Slightly volatile
Capex To Revenue0.07440.12860.0856
Slightly volatile
Cash Per Share9.1511.715110.6612
Slightly volatile
Intangibles To Total Assets0.470.24360.3905
Slightly volatile
Current Ratio1.922.02063.7121
Pretty Stable
Receivables Turnover5.535.824218.1582
Slightly volatile
Graham Number47.6645.392826.2903
Slightly volatile
Capex Per Share1.691.61170.6036
Slightly volatile
Average Receivables1.2 M1.1 M1 M
Very volatile
Revenue Per Share13.1612.53135.8256
Slightly volatile
Interest Debt Per Share31.2529.7647.0003
Slightly volatile
Debt To Assets1.161.10690.3632
Slightly volatile
Operating Cycle242233260
Slightly volatile
Ebt Per Ebit2.091.99231.2291
Slightly volatile
Quick Ratio1.871.96993.6746
Pretty Stable
Net Income Per E B T1.110.90021.01
Very volatile
Cash Ratio0.940.98492.4163
Pretty Stable
Days Of Inventory Outstanding162170597
Slightly volatile
Days Of Sales Outstanding51.7462.669759.8062
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.01.76141.2204
Slightly volatile
Fixed Asset Turnover6.775.23978.3917
Very volatile
Debt Ratio1.161.10690.3632
Slightly volatile
Price Sales Ratio2.092.199311.1795
Pretty Stable
Asset Turnover0.630.49470.6849
Slightly volatile

PTC Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.3 B2.1 B1.5 B
Slightly volatile
Enterprise Value3.9 B3.7 B1.7 B
Slightly volatile

PTC Fundamental Market Drivers

Cash And Short Term Investments876.7 M

PTC Upcoming Events

20th of February 2024
Upcoming Quarterly Report
View
25th of April 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
20th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About PTC Therapeutics Financial Statements

PTC Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although PTC Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in PTC Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on PTC Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue801 K761 K
Total Revenue937.8 M984.7 M
Cost Of Revenue65.5 M36.5 M
Stock Based Compensation To Revenue 0.14  0.13 
Sales General And Administrative To Revenue 0.52  0.80 
Research And Ddevelopement To Revenue 0.71  0.68 
Capex To Revenue 0.13  0.07 
Revenue Per Share 12.53  13.16 
Ebit Per Revenue(0.37)(0.39)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for PTC Stock Analysis

When running PTC Therapeutics' price analysis, check to measure PTC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PTC Therapeutics is operating at the current time. Most of PTC Therapeutics' value examination focuses on studying past and present price action to predict the probability of PTC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PTC Therapeutics' price. Additionally, you may evaluate how the addition of PTC Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY